Zimmer Biomet Holdings, Inc. (ZBH)
Unveiling Zimmer (ZBH) Q4 Outlook: Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Zimmer (ZBH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.
Zimmer Biomet Set to Report Q4 Earnings: What's in Store?
ZBH's Hips business is expected to have witnessed growth banking on its suite of navigation solutions in direct anterior stems and surgical impactors.
Emerging Market Expansion Supports ZBH Stock Amid Macro Issues
Zimmer Biomet is witnessing strong market share gains within reconstructive Knees and Hips in key geographies despite macroeconomic challenges.
Should You Consider Retaining ZBH Stock in Your Portfolio Now?
Zimmer Biomet's robust efforts to expand the Knee business and a gradually stabilizing musculoskeletal market appear promising.
Zimmer Biomet: Back On Offense With Strong Cash Flow Outlook
Zimmer Biomet Holdings (ZBH) is expanding its product portfolio and improving cash flow, positioning it for long-term profitability and financial health. ZBH is undervalued compared to peers, with significant growth potential driven by innovation, acquisitions, and operational efficiency improvements. The company's focus on high-growth markets and improving profitability metrics indicate a strong future outlook, despite past underperformance.
ZBH Stock to Benefit From Global Expansion Despite Macro Issues
Zimmer Biomet is witnessing strong market share gains within reconstructive Knees and Hips in key geographies despite macroeconomic challenges.
ZBH Stock Might Rise Following FDA Nod for OsseoFit
Zimmer Biomet's OsseoFit Stemless Shoulder System gets FDA 510(k) approval. The company expects to launch the system in the first quarter of 2025.
Reasons to Retain ZBH Stock in Your Portfolio for Now
Zimmer Biomet's robust efforts to expand market share and a gradually stabilizing musculoskeletal market appear promising.
ZBH Stock Might Rise Following FDA Nod for Knee Implant Component
Zimmer Biomet's Persona SoluTion Porous Plasma Spray Femur gets FDA 510(k) approval. The company expects to launch the system in the first quarter of 2025.
Why Is Zimmer (ZBH) Up 4.8% Since Last Earnings Report?
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock?
ZBH Stock Gains From FDA Nod for Oxford Cementless Partial Knee
Zimmer Biomet receives FDA nod for the Oxford Cementless Partial Knee. It is a PMA Supplement approval.
ZBH Stock Gains From Receiving CE Mark for Persona Revision Knee System
Zimmer Biomet gets CE Mark Certification for Persona Revision Knee System, followed by the successful introduction in the United States and other markets.
